Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Middle East and Africa Bacteriophages Therapy Market – Industry Trends and Forecast to 2028

Pharmaceutical | Published Report | Aug 2021 | MEA | 350 Pages | No of Tables: 82 | No of Figures: 48

Report Description

Middle East and Africa Bacteriophages Therapy Market, By Target (Escherichia Coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella, Others), Type (Lytic, Lysogenic), Base (Sterile Broth Culture, Water-Soluble Jelly Base), Application (Bacterial Dysentery, Infections Of Skin And Nasal Mucosa, Suppurative Skin Infection, Lung And Pleural Infections, Postoperative Wound Infections, Others), Route Of Administration (Oral, Parenteral, Rectal, Dermal, Others), End-User (Hospitals, Speciality Clinics, Academic Research And Institutes, Others), Distribution Channel (Direct Tender, Third Party Distributors), Country Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt  and Rest of the Middle East and Africa- Industry Trends And Forecast to 2028.


Market Analysis and Insights: Middle East and Africa Bacteriophages Therapy Market

Middle East and Africa bacteriophages therapy market are expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.1% in the forecast period of 2021 to 2028 and is expected to reach USD 1.07 million by 2028.

Bacteriophage, also called phage or bacterial virus, is any of a group of viruses that infect bacteria and are used to treat bacterial infections. This could be used as an alternative to antibiotics when bacteria develop resistance. Bacteriophages are much more specific than antibiotics. They are typically harmless not only to the host organism but also to other beneficial bacteria, such as the gut microbiota, reducing the chances of opportunistic infections. The increasing prevalence of antibiotic-resistant infections and increasing research and development activities are the major drivers which propelled the demand of the market in the forecast period. However, high costs associated with therapy and shortage of skilled professionals are the factors expected to restraint the market growth in the forecast period.

The presence of novel pipeline drugs, strategic initiatives by market players, and a rise in expenditure in the healthcare sector are expected to provide a lucrative growth opportunity for the Middle East and Africa bacteriophages therapy market.  However, the limitation of bacteriophage therapy and lack of proper regulatory guidelines acts as a major challenge in the growth of the Middle East and Africa bacteriophages therapy market.  

The bacteriophages therapy market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal.


Middle East And Africa Bacteriophages Therapy Market Scope and Market Size

The bacteriophages therapy market is segmented on the basis of target, type, base, application, route of administration, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets. 

  • On the basis of target, the Middle East and Africa bacteriophages therapy market is segmented into Escherichia coli, staphylococcus, streptococcus, pseudomonas, salmonella, others. In 2021 staphylococcus segment is expected to dominate the market owing to the increasing focus of manufacturers on the development of advanced drugs in this class.
  • On the basis of type, the Middle East and Africa bacteriophages therapy market is segmented into lytic and lysogenic. In 2021, the lytic segment is expected to dominate the market because of abundance in nature and minor side effects.
  • On the basis of the base, the Middle East and Africa bacteriophages therapy market is segmented into sterile broth culture, water-soluble jelly base. In 2021, sterile broth culture is expected to dominate the market as the bacteriophage is cultured at varying oxygen levels in sterile broth, and more specificity towards the bacteriophages is provided in broth culture.
  • On the basis of application, the Middle East and Africa bacteriophages therapy market is segmented into bacterial dysentery, infections of the skin and nasal mucosa, suppurative skin infection, lung and pleural infections, post-operative wound infections, others. In 2021, the post-operative wound segment is expected to dominate the market due to the growing healthcare infrastructure globally, burgeoning population, and rapid technological advancements.
  • On the basis of route of administration, the Middle East and Africa bacteriophages therapy market is segmented into oral, parenteral, rectal, dermal, others. In 2021, the oral segment is expected to dominate the market due to painless self -administration, and absorption in the whole length of GI.
  • On the basis of end-user, the Middle East and Africa bacteriophages therapy market is segmented into hospitals, specialty clinics, academic research and institutes, others. In 2021, the hospital’s segment is expected to dominate the market due to safety and continuous care, along with patient empowerment.
  • On the basis of distribution channels, the Middle East and Africa bacteriophages therapy market is segmented into direct sales and third-party distributors. In 2021, the direct tender segment is expected to dominate the market due to stronger customer orientation towards internal users and direct communication with suppliers.

Bacteriophages Therapy Market Country Level Analysis

The bacteriophages therapy market is analyzed, and market size information is provided on the basis of target, type, base, application, route of administration, end-user, and distribution channels.

The countries covered in the bacteriophages therapy market report are Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, the rest of the Middle East and Africa.

The direct tender segment in the Middle East & Africa region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of stronger customer orientation towards internal users and direct communication with suppliers. South Africa is expected to dominate the bacteriophage therapy market in the Middle East and Africa due to the rise in patient population and interest of key players in expanding their market presence in the middle east & Africa.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Private Sector Funding And Technological Advancements Are Boosting The Market Growth Of Bacteriophages Therapy. 

The bacteriophages therapy market also provides you with detailed market analysis for every country’s growth in the bacteriophage therapy industry with drugs sales, the impact of advancement, technology, and changes in regulatory scenarios with their support for the OCD drugs market. The data is available for the historical period 2011 to 2019.

Competitive Landscape and Bacteriophages Therapy Market Share Analysis

Bacteriophages therapy market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the bacteriophages therapy market.

Collaboration, product launch, business expansion, award and recognition, joint ventures, and other strategies by the market player is enhancing the company market in the bacteriophage therapy market, which also provides the benefit for the organization to improve their offering for bacteriophage therapy.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TAREGET LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTERS FIVE FORCES MODEL

4.2 PESTEL ANALYSIS

5 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: REGULATIONS

5.1 THE U.S. REGULATORY GUIDELINES FOR BACTERIOPHAGES

5.2 EUROPE REGULATORY GUIDELINE FOR BACTERIOPHAGE

5.3 JAPAN REGULATORY GUIDELINE FOR BACTERIOPHAGE

5.4 AUSTRALIA REGULATORY GUIDELINE FOR BACTERIOPHAGE

6 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: REGIONAL SUMMARY

7 RESEARCH AND DEVELOPMENT ANALYSIS: MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET

7.1 PIPELINE ANALYSIS

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 INCREASING PREVALENCE OF ANTIBIOTIC-RESISTANT INFECTIONS

8.1.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

8.1.3 INCREASING GOVERNMENT FUNDING

8.1.4 INCREASING PRIVATE SECTOR FUNDING

8.1.5 TECHNOLOGICAL ADVANCEMENTS

8.2 RESTRAINTS

8.2.1 HIGH COST ASSOCIATED WITH BACTERIOPHAGE THERAPY

8.2.2 LACK OF SKILLED PROFESSIONALS

8.2.3 SIDE-EFFECTS OF BACTERIOPHAGE THERAPY

8.2.4 AVAILABILITY OF ALTERNATIVE THERAPIES FOR ANTIBIOTIC RESISTANCE

8.3 OPPORTUNITIES

8.3.1 PRESENCE OF NOVEL PIPELINE DRUGS

8.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

8.3.3 INCREASING HEALTHCARE EXPENDITURE

8.4 CHALLENGES

8.4.1 LIMITATIONS OF BACTERIOPHAGE THERAPY

8.4.2 LACK OF PROPER REGULATORY GUIDELINES

9 IMPACT OF COVID-19 ON MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET

9.1 IMPACT ON THE PRICE

9.2 IMPACT ON DEMAND

9.3 IMPACT ON SUPPLY

9.4 STRATEGIC INITIATIVES BY MANUFACTURERS

9.5 CONCLUSION

10 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET

10.1 OVERVIEW

10.2 STAPHYLOCOCCUS

10.3 ESCHERICHIA COLI

10.4 PSEUDOMONAS

10.5 STREPTOCOCCUS

10.6 SALMONELLA

10.7 OTHERS

11 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE

11.1 OVERVIEW

11.2 LYTIC

11.3 LYSOGENIC

12 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE

12.1 OVERVIEW

12.2 STERILE BROTH CULTURE

12.3 WATER-SOLUBLE JELLY BASE

13 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION

13.1 OVERVIEW

13.2 POSTOPERATIVE WOUND INFECTIONS

13.3 INFECTIONS OF SKIN AND NASAL MUCOSA

13.4 BACTERIAL DYSENTERY

13.5 SUPPURATIVE SKIN INFECTIONS

13.6 LUNG AND PLEURAL INFECTION

13.7 OTHERS

14 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION

14.1 OVERVIEW

14.2 ORAL

14.2.1 LIQUID

14.2.2 TABLET

14.3 DERMAL

14.4 PARENTERAL

14.4.1 INTRAVENOUSLY

14.4.2 INTRAPLEURAL INJECTIONS

14.5 OTHERS

15 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 SPECILAITY CLINICS

15.4 ACADEMIC RESEARCH & INSTITUTES

15.5 OTHERS

16 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 DIRECT TENDER

16.3 THIRD PARTY DISTRIBUTORS

17 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY REGION

17.1 MIDDLE EAST & AFRICA

17.1.1 SOUTH AFRICA

17.1.2 SAUDI ARABIA

17.1.3 ISRAEL

17.1.4 EGYPT

17.1.5 REST OF MIDDLE EAST & AFRICA

18 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

19 SWOT ANALYSIS

20 COMPANY PROFILE

20.1 MICROGEN

20.1.1 COMPANY SNAPSHOT

20.1.2 COMPANY SHARE ANALYSIS

20.1.3 PRODUCT PORTFOLIO

20.1.4 RECENT DEVELOPMENTS

20.2 ADAPTIVE PHAGE THERAPEUTICS

20.2.1 COMPANY SNAPSHOT

20.2.2 COMPANY SHARE ANALYSIS

20.2.3 PRODUCT PORTFOLIO

20.2.4 RECENT DEVELOPMENTS

20.3 PHAGELUX,INC

20.3.1 COMPANY SNAPSHOT

20.3.2 COMPANY SHARE ANALYSIS

20.3.3 PRODUCT PORTFOLIO

20.3.4 RECENT DEVELOPMENTS

20.4 LOCUS BIOSCIENCES, INC.

20.4.1 COMPANY SNAPSHOT

20.4.2 COMPANY SHARE ANALYSIS

20.4.3 PRODUCT PORTFOLIO

20.4.4 RECENT DEVELOPMENTS

20.5 ATCC

20.5.1 COMPANY SNAPSHOT

20.5.2 COMPANY SHARE ANALYSIS

20.5.3 PRODUCT PORTFOLIO

20.5.4 RECENT DEVELOPMENTS

20.6 INTRALYTIX, INC.

20.6.1 COMPANY SNAPSHOT

20.6.2 PRODUCT PORTFOLIO

20.6.3 RECENT DEVELOPMENTS

20.7 MICREOS

20.7.1 COMPANY SNAPSHOT

20.7.2 PRODUCT PORTFOLIO

20.7.3 RECENT DEVELOPMENT

20.8 PYLUM

20.8.1 COMPANY SNAPSHOT

20.8.2 TECHNOLOGY PORTFOLIO

20.8.3 RECENT DEVELOPMENTS

20.9 FIXED-PHAGE LIMITED

20.9.1 COMPANY SNAPSHOT

20.9.2 PRODUCT PORTFOLIO

20.9.3 RECENT DEVELOPMENTS

20.1 ARMATA PHARMACEUTICALS, INC.

20.10.1 COMPANY SNAPSHOT

20.10.2 PRODUCT PORTFOLIO

20.10.3 RECENT DEVELOPMENTS

20.11 ARTHUR ANDREW MEDICAL

20.11.1 COMPANY SNAPSHOT

20.11.2 PRODUCT PORTFOLIO

20.11.3 RECENT DEVELOPMENT

20.12 CYTOPHAGE TECHNOLOGIES INC.

20.12.1 COMPANY SNAPSHOT

20.12.2 PRODUCT PORTFOLIO

20.12.3 RECENT DEVELOPMENT

20.13 ENBIOTIX, INC.

20.13.1 COMPANY SNAPSHOT

20.13.2 PRODUCT PORTFOLIO

20.13.3 RECENT DEVELOPMENTS

20.14 INTODEWORLD, INC.

20.14.1 COMPANY SNAPSHOT

20.14.2 PRODUCT PORTFOLIO

20.14.3 RECENT DEVELOPMENT

20.15 NEXTBIOTICS

20.15.1 COMPANY SNAPSHOT

20.15.2 TECHNOLOGY PORTFOLIO

20.15.3 RECENT DEVELOPMENT

20.16 PHERECYDES PHARMA

20.16.1 COMPANY SNAPSHOT

20.16.2 PRODUCT PORTFOLIO

20.16.3 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

List of Table

TABLE 1 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA STAPHYLOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA ESCHERICHIA COLI IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA PSEUDOMONAS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA STREPTOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA SALMONELLA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA LYTIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA LYSOGENIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA STERILE BROTH CULTURE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA WATER-SOLUBLE JELLY BASE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA POSTOPERATIVE WOUND INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA INFECTIONS OF SKIN AND NASAL MUCOSA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA BACTERIAL DYSENTERY IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA SUPPURATIVE SKIN INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA LUNG AND PLEURAL INFECTION IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA DERMAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA HOSPITALS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA SPECILIATY CLINICS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA ACADEMIC RESEARCH & INSTITUTES IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA DIRECT TENDER IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA THIRD PARTY DISTRIBUTORS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 46 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 47 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 48 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 49 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 50 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 51 SOUTH AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 52 SOUTH AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 53 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 54 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 55 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 56 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 57 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 58 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 59 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 60 SAUDI ARABIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 61 SAUDI ARABIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 62 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 63 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 64 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 65 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 67 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 68 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 69 ISRAEL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 70 ISRAEL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 71 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 72 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 73 EGYPT BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 74 EGYPT BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 75 EGYPT BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 76 EGYPT BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 77 EGYPT BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 78 EGYPT ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 79 EGYPT PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 80 EGYPT BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 81 EGYPT BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 82 REST OF MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET : MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: SEGMENTATION

FIGURE 11 RISING INCIDENCE OF ANTIBIOTIC-RESISTANT INFECTIONS AND TECHNOLOGICAL ADVANCEMENTS ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 STAPHYLOCOCCUS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET IN 2021 & 2028

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET

FIGURE 15 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2020

FIGURE 16 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2021-2028 (USD MILLION)

FIGURE 17 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, CAGR (2021-2028)

FIGURE 18 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, LIFELINE CURVE

FIGURE 19 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2020

FIGURE 20 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2021-2028 (USD MILLION)

FIGURE 21 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 22 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY BASE, 2020

FIGURE 24 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY BASE, 2021-2028 (USD MILLION)

FIGURE 25 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY BASE, CAGR (2021-2028)

FIGURE 26 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY BASE, LIFELINE CURVE

FIGURE 27 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2020

FIGURE 28 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 29 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 30 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 31 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 32 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

FIGURE 33 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 34 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY END USER, 2020

FIGURE 36 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 37 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY END USER, CAGR (2021-2028)

FIGURE 38 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY END USER, LIFELINE CURVE

FIGURE 39 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 40 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 41 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 42 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)

FIGURE 44 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)

FIGURE 45 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)

FIGURE 46 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)

FIGURE 47 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)

FIGURE 48 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)

View Infographics

FIGURE 1 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET : MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: SEGMENTATION

FIGURE 11 RISING INCIDENCE OF ANTIBIOTIC-RESISTANT INFECTIONS AND TECHNOLOGICAL ADVANCEMENTS ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 STAPHYLOCOCCUS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET IN 2021 & 2028

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET

FIGURE 15 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2020

FIGURE 16 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2021-2028 (USD MILLION)

FIGURE 17 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, CAGR (2021-2028)

FIGURE 18 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, LIFELINE CURVE

FIGURE 19 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2020

FIGURE 20 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2021-2028 (USD MILLION)

FIGURE 21 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 22 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY BASE, 2020

FIGURE 24 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY BASE, 2021-2028 (USD MILLION)

FIGURE 25 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY BASE, CAGR (2021-2028)

FIGURE 26 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY BASE, LIFELINE CURVE

FIGURE 27 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2020

FIGURE 28 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 29 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 30 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 31 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 32 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

FIGURE 33 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 34 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY END USER, 2020

FIGURE 36 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 37 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY END USER, CAGR (2021-2028)

FIGURE 38 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY END USER, LIFELINE CURVE

FIGURE 39 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 40 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 41 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 42 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)

FIGURE 44 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)

FIGURE 45 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)

FIGURE 46 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)

FIGURE 47 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)

FIGURE 48 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 8500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19